Objective To evaluate several alternative measures of forced expiratory volume in 1 second percent predicted (FEV 1 %pred) variability as potential predictors of future FEV 1 %pred decline in patients with cystic fibrosis. Study design We included 13 827 patients age ≥6 years from the Epidemiologic Study of Cystic Fibrosis 1994-2002 with ≥4 FEV 1 %pred measurements spanning ≥366 days in both a 2-year baseline period and a 2-year follow-up period. We predicted change from best baseline FEV 1 %pred to best follow-up FEV 1 %pred and change from baseline to best in the second follow-up year by using multivariable regression stratified by 4 lung-disease stages. We assessed 5 measures of variability (some as deviations from the best and some as deviations from the trend line) both alone and after controlling for demographic and clinical factors and for the slope and level of FEV 1 %pred. Results All 5 measures of FEV 1 %pred variability were predictive, but the strongest predictor was median deviation from the best FEV 1 %pred in the baseline period. The contribution to explanatory power (R 2 ) was substantial and exceeded the total contribution of all other factors excluding the FEV 1 %pred rate of decline. Adding the other variability measures provided minimal additional value. Conclusions Median deviation from the best FEV 1 %pred is a simple metric that markedly improves prediction of FEV 1 %pred decline even after the inclusion of demographic and clinical characteristics and the FEV 1 %pred rate of decline. The routine calculation of this variability measure could allow clinicians to better identify patients at risk and therefore in need of increased intervention.
|Journal||Journal of Pediatrics|
|State||Published - May 1 2016|
Bibliographical noteFunding Information:
The Epidemiologic Study of Cystic Fibrosis was supported by Genentech, Inc (San Francisco, CA). W.M., D.VanD., J.W., and M.K. received honoraria from Genentech for serving as members of the Scientific Advisory Group for the Epidemiologic Study of Cystic Fibrosis and have served as consultants to Genentech. D.P. and A.F. are employees of ICON Clinical Research, which was paid by Genentech for providing analytical services for this study. J.W. was previously an employee of Genentech.
© 2016 Elsevier Inc.
- %pred Percent predicted
- CF Cystic fibrosis
- FEV Forced expiratory volume in 1 second
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health